Join Growin Stock Community!

Jupiter neurosciences, inc.JUNS.US Overview

US StockHealthcare
(No presentation for JUNS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

JUNS AI Insights

JUNS Overall Performance

JUNS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

JUNS Recent Performance

-4.62%

Jupiter neurosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

JUNS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

JUNS Key Information

JUNS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

JUNS Profile

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

Price of JUNS

JUNS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.22
PE Ratio (TTM)
-
Forward PE
3.38
PS Ratio (TTM)
-
PB Ratio
340.14
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.22
PE Ratio (TTM)
-
Forward PE
3.38
PS Ratio (TTM)
-
PB Ratio
340.14
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is JUNS's latest earnings report released?

    The most recent financial report for Jupiter neurosciences, inc. (JUNS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating JUNS's short-term business performance and financial health. For the latest updates on JUNS's earnings releases, visit this page regularly.

  • How much cash does JUNS have?

    At the end of the period, Jupiter neurosciences, inc. (JUNS) held Total Cash and Cash Equivalents of 723.8K, accounting for 0.28 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is JUNS's EPS continuing to grow?

    According to the past four quarterly reports, Jupiter neurosciences, inc. (JUNS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of JUNS?

    Jupiter neurosciences, inc. (JUNS)'s Free Cash Flow (FCF) for the period is -1.15M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 2,610.1% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

JUNS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1